Synergistic bacterial compositions and methods of production and use thereof
Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
1. A composition comprising at least a first species of an isolated bacterium capable of forming a spore, a second species of isolated bacterium capable of forming a spore, and a third species of isolated bacterium capable of forming a spore, wherein the first species, the second species, and the third species are not identical, wherein the first species comprises Clostridium bolteae , the second species comprises Clostridium orbiscindens , and the third species comprises Blautia producta , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 609, wherein a combination of the first species, the second species, and the third species is capable of decreasing and/or inhibiting the growth and/or colonization of Clostridium difficile , as measured by a CivSim assay, and wherein the composition further comprises an enteric coating.
2. A single dose unit comprising the composition of claim 1 .
3. A pharmaceutical formulation comprising an effective amount of the composition of claim 1 .
4. The composition of claim 1 , wherein the first species, the second species, the third species, or combinations thereof are in the form of spores.
5. The composition of claim 1 , wherein the first species, the second species, the third species, or combinations thereof are lyophilized.
6. The composition of claim 1 , wherein the first species, the second species, the third species, or combinations thereof are present in the composition at the same dosage amount.
7. A method of producing a bacterial composition, comprising combining at least a first species of isolated bacterium capable of forming a spore, a second species of isolated bacterium capable of forming a spore, and a third species of isolated bacterium capable of forming a spore, wherein the first species, the second species, and the third species are not identical, wherein the first species comprises Clostridium bolteae , the second species comprises Clostridium orbiscindens , and the third species comprises Blautia producta , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to the 16S rDNA sequence set forth in SEQ ID NO: 609, wherein a combination of the first species, the second species, and the third species can decrease and/or inhibit the growth and/or colonization of Clostridium difficile , as measured by a CivSim assay, and wherein the bacterial composition further comprises an enteric coating.
8. The composition of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 609.
9. The composition of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 609.
10. The composition of claim 1 , wherein the Clostridium orbiscindens comprises the 16S rDNA sequence set forth in SEQ ID NO: 609.
11. The pharmaceutical formulation of claim 3 , further comprising an effective amount of an anti-fungal agent, an anti-bacterial agent, an anti-viral agent, an anti-parasitic agent, or combinations thereof.
12. The composition of claim 1 , wherein the Clostridium bolteae comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 559.
13. The composition of claim 1 , wherein the Clostridium bolteae comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 559.
14. The composition of claim 1 , wherein the Clostridium bolteae comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 559.
15. The composition of claim 1 , wherein the Clostridium bolteae comprises the 16S rDNA sequence set forth in SEQ ID NO: 559.
16. The composition of claim 1 , wherein the Blautia producta comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 379.
17. The composition of claim 1 , wherein the Blautia producta comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 379.
18. The composition of claim 1 , wherein the Blautia producta comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 379.
19. The composition of claim 1 , wherein the Blautia producta comprises the 16S rDNA sequence set forth in SEQ ID NO: 379.
20. The pharmaceutical formulation of claim 3 , which is formulated for oral administration.